As we look ahead to March 18, 2024, Acurx Pharmaceuticals (NASDAQ: ACXP) is gearing up to unveil its latest quarterly earnings report. Analysts are forecasting an earnings per share (EPS) of $-0.26 for the pharmaceutical company.
Investors are hopeful for positive guidance or projected growth in the coming quarter from Acurx Pharmaceuticals. Looking back at past performance, in the previous quarter, the company exceeded EPS expectations by $0.03, leading to a 1.18% surge in share price the following day.
Reviewing historical data for Acurx Pharmaceuticals:
– Q3 2023: EPS Estimate -0.27, EPS Actual -0.24, Price Change +1.0%
– Q2 2023: EPS Estimate -0.29, EPS Actual -0.28, Price Change +1.0%
– Q1 2023: EPS Estimate -0.29, EPS Actual -0.25, Price Change -8.0%
– Q4 2022: EPS Estimate -0.35, EPS Actual -0.28, Price Change -7.00%
As of March 14, Acurx Pharmaceuticals shares were trading at $2.71, reflecting a negative return of 7.19% over the past year. This data offers valuable insights into what may be in store for Acurx Pharmaceuticals’s upcoming earnings report and how historical performance has impacted stock prices previously.
ACXP Stock Shows Promising Price Momentum on March 15, 2024
On March 15, 2024, ACXP stock showed promising signs of price momentum as it traded near the bottom of its 52-week range and below its 200-day simple moving average. The stock saw a significant increase in its price, closing the day with a $0.17 rise, representing a 6.46% increase.
The day started off on a positive note for ACXP, as it opened at $2.79, $0.08 higher than its previous close. This initial jump in price set the tone for the rest of the trading day, with the stock continuing to climb throughout the session.
The price momentum exhibited by ACXP on March 15th could be attributed to positive news or developments surrounding the company, sector-wide trends, or overall market sentiment. Investors may have also been drawn to the stock due to its relatively low valuation compared to its 52-week range and moving average.
While it is difficult to predict future stock performance based on a single day’s trading activity, the positive price movement seen in ACXP on March 15th may be a bullish signal for investors. It will be interesting to see if this momentum continues in the days and weeks ahead, or if the stock encounters any resistance at its 200-day moving average.
Investors should conduct their own research and due diligence before making any investment decisions, especially when it comes to stocks exhibiting price momentum like ACXP. By staying informed and monitoring market trends, investors can make more informed choices and potentially capitalize on opportunities for growth in their portfolios.
ACXP Stock Performance Analysis: Positive Trends in Net Income and EPS Growth
On March 15, 2024, investors closely monitored the stock performance of ACXP, a company whose total revenue data was unavailable. Despite the lack of this key financial metric, investors were able to glean some insights into the company’s financial health based on its net income and earnings per share figures.
According to data from CNN Money, ACXP reported a net income of -$12.09 million over the past year, with a significant improvement in the most recent quarter, where the net income stood at -$3.11 million. This represents a 5.14% increase in net income since the previous year and a 9.59% increase since the last quarter. While the company is still reporting negative net income figures, the positive trend in these numbers is a promising sign for investors.
Similarly, the earnings per share (EPS) figures for ACXP also showed improvement over the same periods. The EPS over the past year was -$1.12, which increased by 10.4% since the previous year. In the most recent quarter, the EPS was -$0.24, showing a significant 15.28% increase since the last quarter. These improvements in EPS indicate that the company is becoming more efficient in generating profits on a per-share basis.
Overall, the stock performance of ACXP on March 15, 2024, reflected the positive trends in the company’s financial metrics. While the lack of total revenue data may have limited investors’ ability to fully assess the company’s performance, the improvements in net income and EPS figures suggest that ACXP is moving in the right direction. As always, investors should continue to closely monitor the company’s financial reports and market performance to make informed investment decisions.
